The University of Texas MD Anderson Cancer Center, Houston, USA.
Med Mycol. 2011 Apr;49(3):285-8. doi: 10.3109/13693786.2010.530300. Epub 2010 Oct 28.
Drug combinations are increasingly being explored as a means of improving outcomes in cases of invasive aspergillosis. However, the optimal methods for assessing in vitro drug combinations are unclear. We investigated whether echinocandin drug combinations have potentially useful interactions against Aspergillus fumigatus. We explored the in vitro interactions of three echinocandins (caspofungin [CSP], anidulafingin [ANF], and micafungin [MCF]) by three methods, i.e., (i) checkerboard assay, (ii) disk diffusion assay, and (iii) E-test/agar dilution. The checkerboard experiments revealed different interactions between echinocandin pairs depending on the drug combination tested. Specifically, the combination of CSF and either ANF or MCF yielded a fractional inhibitory concentration (FIC) index range of 0.15-2.0. Whereas the combination of MCF and ANF yielded an FIC index range of 0.19-0.31, consistent with synergistic interaction. In contrast, all echinocandin pairs appeared indifferent by the disk diffusion method. Moreover, the combination of MCF and ANF appeared antagonistic when the two drugs were tested using the E-test/agar dilution method with both the FKS1 wild-type and echinocandin-resistant fks1 mutant strains. Our results highlight methodological problems inherent in in vitro antifungal combination testing. We did not find compelling evidence of inter-echinocandin synergy that could serve as a basis for further in vivo experimentation.
药物联合治疗越来越多地被探索用于提高侵袭性曲霉菌病的治疗效果。然而,评估体外药物联合治疗的最佳方法尚不清楚。我们研究了棘白菌素类药物联合治疗是否对烟曲霉具有潜在的协同作用。我们通过三种方法,即棋盘微量稀释法、纸片扩散法和 E 试验/琼脂稀释法,研究了三种棘白菌素(卡泊芬净[CSP]、阿尼芬净[ANF]和米卡芬净[MCF])的体外相互作用。棋盘微量稀释实验结果表明,不同的棘白菌素组合之间存在不同的相互作用,这取决于所测试的药物组合。具体来说,CSP 与 ANF 或 MCF 的组合产生的部分抑菌浓度(FIC)指数范围为 0.15-2.0。而 MCF 与 ANF 的组合产生的 FIC 指数范围为 0.19-0.31,提示存在协同作用。相比之下,纸片扩散法显示所有棘白菌素组合均为无关作用。此外,当使用 E 试验/琼脂稀释法对 MCF 和 ANF 进行测试时,无论是 FKS1 野生型还是棘白菌素耐药的 fks1 突变株,这两种药物的组合均表现为拮抗作用。我们的结果突出了体外抗真菌药物联合治疗测试中固有的方法学问题。我们没有发现棘白菌素类药物之间有协同作用的有力证据,无法为进一步的体内实验提供依据。